It is noteworthy that an on-going clinical trial is investigating pembrolizumab, an anti-PD-1 antibody, in advanced BRCA1- and BRCA2-mutated breast cancer patients (ClinicalTrials.gov identifier: NCT03025035). Here, BRCA2 is linked to breast carcinoma.